Valuation : Geron Corporation

Market Cap 1.01B 868M 817M 746M 1.4B 95.24B 1.4B 9.65B 3.74B 48.86B 3.79B 3.71B 157B P/E 2026 *
-37.4x
P/E 2027 * 23.1x
Enterprise Value 1.01B 868M 817M 746M 1.4B 95.24B 1.4B 9.65B 3.74B 48.86B 3.79B 3.71B 157B EV / Sales 2026 *
4.27x
EV / Sales 2027 * 2.95x
Free-Float
99.92%
Yield 2026 *
-
Yield 2027 * -
1 day+3.97%
1 week+3.97%
Current month+5.37%
3 months+34.19%
6 months+2.61%
Current year+18.94%
1 week 1.46
Extreme 1.46
1.62
1 month 1.43
Extreme 1.43
1.65
Current year 1.08
Extreme 1.08
2.01
1 year 1.04
Extreme 1.04
2.01
3 years 1.04
Extreme 1.04
5.34
5 years 0.99
Extreme 0.9899
5.34
10 years 0.75
Extreme 0.75
6.99
Manager TitleAgeSince
Chief Executive Officer 54 06/08/2025
Director of Finance/CFO 59 24/09/2023
Chief Tech/Sci/R&D Officer - 30/09/2025
Director TitleAgeSince
Director/Board Member 76 20/05/2010
Director/Board Member 72 27/09/2012
Director/Board Member 55 25/03/2019
Date Insider Type Main position Quantity % Market Cap. Importance
30/06/26 Free

Director

6,103 0.0010%
20/05/26 Free

Director

220,000 0.0343%
20/05/26 Free

Director

220,000 0.0343%
Change 5-day change 1-year change 3-year change Capi.($)
+3.97%+3.97%+12.14%-35.92% 1.01B
-1.79%-2.27%+43.23%+99.78% 67.98B
-3.22%-1.23%+33.37%+80.47% 64.94B
-0.31%+6.54%-12.96%+377.83% 27.58B
+0.86%+1.65%-7.74%-13.58% 26.06B
-1.42%-0.74%+24.37%+15.84% 25.74B
-0.97%+1.08%+23.35%-18.35% 20.09B
-2.96%-15.21%+216.20%+375.70% 17.16B
+0.20%-1.37%-6.86%+549.54% 14.92B
-0.20%+8.37%+55.78%+165.57% 14.62B
Average -0.58%+0.63%+38.09%+159.69% 28.01B
Weighted average by Cap. -1.50%+0.19%+35.98%+139.75%

Financials

2026 *2027 *
Net sales 236M 203M 191M 175M 327M 22.31B 328M 2.26B 877M 11.45B 887M 868M 36.87B 342M 294M 277M 253M 473M 32.29B 474M 3.27B 1.27B 16.57B 1.28B 1.26B 53.37B
Net income -27.18M -23.39M -22.01M -20.1M -37.61M -2.57B -37.71M -260M -101M -1.32B -102M -99.84M -4.24B 50.14M 43.15M 40.6M 37.09M 69.38M 4.73B 69.56M 480M 186M 2.43B 188M 184M 7.83B
Net Debt - -
Logo Geron Corporation
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Employees
258
Date Price Change Volume
04/09/26 US$1.570 +3.97% 11,478,945
03/09/26 US$1.510 -5.03% 14,234,297
02/09/26 US$1.590 +7.43% 26,890,023
01/09/26 US$1.480 -0.67% 7,886,442
31/08/26 US$1.490 -1.32% 7,247,301
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.570USD
Average target price
4.250USD
Spread / Average Target
+170.70%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GERN Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!